On January 13, 2026, Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, announced an oversubscribed $80 million Seed financing.

As part of the financing, the company has rebranded from VantAI to Proxima to reflect its singular focus on building out both the technology and data layer needed to unlock proximity-based therapeutics. The new funding will accelerate the advancement of first-in-class proximity-modulating therapeutics, expanding the druggable target space and enabling more reliable discovery of novel mechanisms across oncology, immunology, and other disease areas.

The Wilson Sonsini team that advised Proxima on the transaction was led by Danielle Naftulin, Davelyn Bulovas, and Nara Jo, with invaluable support from Mark Bellomy, Mike Danaher, Farah Gerdes, Josh Gruenspecht, Michael Klippert, John McGaraghan, Anne Seymour, Grace Beck, Nimit Dhir, Morgan Rhodes Logan, Gopika Mesrobian, Hayden Smith, and Tim Ingram.

For more information, please see Proxima’s news release.